POS1048 SAFETY AND EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A RANDOMISED PHASE 2 TRIAL
P. J. Mease(Providence College), Sibabrata Banerjee(Bristol-Myers Squibb (United States)), F. Behrens(Goethe University Frankfurt), Nikolay Delev(Bristol-Myers Squibb (Sweden)), A. Kivitz(Altoona Center for Clinical Research), Shimon Korish(Bristol-Myers Squibb (United States)), Atul Deodhar(Oregon Health & Science University), Thomas Lehman(Hospital for Special Surgery), D. van der Heijde(Leiden University Medical Center), Miroslawa Nowak(Bristol-Myers Squibb (United States)), Jeffrey Neal(University of Kentucky), M. Nys(Bristol-Myers Squibb (United States))
Cited by 5
Related Papers
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
|Annals of the Rheumatic Diseases|2018|88
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis
|Arthritis Research & Therapy|2019|80